Retaspimycin (IPI-504)
In clinical trials. Also known as IPI504, Retaspimycin HCl.
General information
Class/mechanism: Hsp90 (heat shock protein 90) inhibitor. Hsp90 is a molecular chaperone that stabilizes various cellular proteins, such as growth factor receptors and molecules involved in signal transduction. Hsp90 is overexpressed in cancer cells and may help to stabilize less stable proteins produced by DNA mutations. By inhibiting Hsp90, retaspimycin may accelerate degradation of growth factors and increase the sensitivity of cancer cells to environmental stress, leading to apoptosis of tumor cells.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Clinical trials
- Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)
- A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer (IPI-504-04)
- Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
- Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
- Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
- A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
Patient drug information
No information available.